Investors & Media

Ionis reports first quarter 2023 financial results

QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance CARLSBAD, Calif. , May 3, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc.

Read more
You are now leaving to visit